Novartis strengthens its breast cancer pipeline with $3bn Synnovation acquisition

CE2026-03-20T12:04:00

Deal to help address the significant unmet need in HR+/HER2- breast cancer and other advanced solid tumours.

Novartis is acquiring Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, for up to $3 billion, gaining access to a portfolio of investigational PI3Kα inhibitors for HR+/HER2- breast cancer.

Synnovation’s lead asset SNV4818 is an oral PI3Kα inhibitor in Phase I/II development for breast cancer and other advanced solid tumours.

Dr Shreeram Aradhye, President of Development at Novartis, said: “While mutated PI3Kα is a well‑established driver in HR+/HER2‑ breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile.

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member